Letybo (Botulinum Toxin Type A)

Botulinum toxin type A cleaves the SNAP‑25 protein, which is essential for the release of acetylcholine at the neuromuscular junction. By blocking this neurotransmitter, the toxin prevents muscle fiber activation, resulting in a temporary, localized paralysis of the injected muscle.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, muscle size, and patient response. Dosing regimens are determined during the clinical assessment and are not standardized across all patients.

Safety data for Letybo in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Letybo contains botulinum toxin type A, the same active molecule found in other branded preparations. Differences may lie in formulation specifics, vial size, and regulatory approvals. Clinical efficacy and safety are generally comparable when administered by experienced clinicians, but product‑specific data should be reviewed for each indication.

Letybo must be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product to maintain potency and sterility.

Letybo is given by intramuscular injection using a sterile technique. The clinician selects injection sites based on the targeted muscle group and condition, often guided by anatomical landmarks or electromyographic assistance to ensure accurate placement.

Serious risks include the spread of toxin effect leading to generalized muscle weakness, dysphagia, respiratory compromise, and rare systemic botulism‑like symptoms. Anaphylactic reactions can also occur. Patients should be monitored closely after injection, especially if they have pre‑existing neuromuscular disorders.

Letybo is contraindicated in individuals with known hypersensitivity to botulinum toxin type A or any excipients in the formulation. Caution is advised for patients with neuromuscular junction disorders such as myasthenia gravis, Lambert‑Eaton syndrome, or those taking interacting medications that increase the risk of weakness.